Publications by authors named "Asuka Oda"

Claim this Profile
M
Myeloma cell growth suppression by osteoblast-derived extracellular vesicles: the creation of a non-permissive niche for myeloma cells by bone-forming osteoblasts.
SooHa Kim, Jumpei Teramachi, Masahiro Hiasa, Ryota Amachi, Ariunzaya Bat-Erdene, Asuka Oda

Haematologica· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elotuzumab-mediated ADCC with Th1-like Vγ9Vδ2 T cells to disrupt myeloma-osteoclast interaction.
Yusuke Inoue, Hirofumi Tenshin, Jumpei Teramachi, Ryohei Sumitani, Asuka Oda

Cancer Sci· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ex vivo expansion and activation of Vγ9Vδ2 T cells by CELMoDs in combination with zoledronic acid.
Yusuke Inoue, Asuka Oda, Yusaku Maeda, Ryohei Sumitani, Masahiro Oura

Int J Hematol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors.
Kimiko Sogabe, Shingen Nakamura, Yoshiki Higa, Hirokazu Miki, Asuka Oda

Int J Hematol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute suppression of translation by hyperthermia enhances anti-myeloma activity of carfilzomib.
Tomoko Maruhashi, Hirokazu Miki, Kimiko Sogabe, Asuka Oda, Ryohei Sumitani

Int J Hematol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic efficacy of the resorcylic acid lactone LL-Z1640-2 for adult T-cell leukaemia/lymphoma.
Masahiro Oura, Takeshi Harada, Asuka Oda, Jumpei Teramachi, Atsushi Nakayama

EJHaem· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors.
Emiko Nakaue, Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Takeshi Harada, Asuka Oda

Int J Hematol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase.
Takeshi Harada, Hiroto Ohguchi, Asuka Oda, Michiyasu Nakao, Jumpei Teramachi

Blood Adv· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Xanthine Oxidase Inhibitor Febuxostat Suppresses Adipogenesis and Activates Nrf2.
Yoshiki Higa, Masahiro Hiasa, Hirofumi Tenshin, Emiko Nakaue, Mariko Tanaka, Asuka Oda

Antioxidants (Basel)· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanical unloading aggravates bone destruction and tumor expansion in myeloma.
Kotaro Tanimoto, Masahiro Hiasa, Hirofumi Tenshin, Jumpei Teramachi, Asuka Oda

Haematologica· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TGF-β-activated kinase-1 inhibitor LL-Z1640-2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF-α and RANKL expression.
Hirofumi Tenshin, Jumpei Teramachi, Mohannad Ashtar, Masahiro Hiasa, Yusuke Inoue, Asuka Oda

Clin Transl Immunology· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma.
Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Ariunzaya Bat-Erdene

Haematologica· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reveromycin A, a novel acid-seeking agent, ameliorates bone destruction and tumor growth in multiple myeloma.
Keiichiro Watanabe, Ariunzaya Bat-Erdene, Hirofumi Tenshin, Qu Cui, Jumpei Teramachi, Asuka Oda

Haematologica· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat.
Mohannad Ashtar, Hirofumi Tenshin, Jumpei Teramachi, Ariunzaya Bat-Erdene, Masahiro Hiasa, Asuka Oda

Cancers (Basel)· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-α and ATRA.
Ariunzaya Bat-Erdene, Shingen Nakamura, Asuka Oda, Masami Iwasa, Jumpei Teramachi

Br J Haematol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ.
Masami Iwasa, Takeshi Harada, Asuka Oda, Ariunzaya Bat-Erdene, Jumpei Teramachi

Oncotarget· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma.
Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Takeshi Harada, Shingen Nakamura

Br J Haematol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective impairment of myeloma cells and their progenitors by hyperthermia.
Hirokazu Miki, Shingen Nakamura, Asuka Oda, Hirofumi Tenshin, Jumpei Teramachi

Oncotarget· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity.
Shiro Fujii, Shingen Nakamura, Asuka Oda, Hirokazu Miki, Hirofumi Tenshin

Br J Haematol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects.
Hirofumi Tenshin, Jumpei Teramachi, Asuka Oda, Ryota Amachi, Masahiro Hiasa

Blood Adv· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alteration.
Ryota Amachi, Masahiro Hiasa, Jumpei Teramachi, Takeshi Harada, Asuka Oda, Yoshiaki Kuroda

Oncotarget· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation.
Derek James Hanson, Shingen Nakamura, Ryota Amachi, Masahiro Hiasa, Asuka Oda

Oncotarget· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors contributing to deep supercooling capability and cold survival in dwarf bamboo (Sasa senanensis) leaf blades.
Masaya Ishikawa, Asuka Oda, Reiko Fukami, Akira Kuriyama

Front Plant Sci· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors.
Takeshi Harada, Shuji Ozaki, Asuka Oda, Daisuke Tsuji, Akishige Ikegame, Yoshiaki Kuroda

PLoS One· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib.
Shingen Nakamura, Hirokazu Miki, Shinsuke Kido, Ayako Nakano, Masahiro Hiasa, Asuka Oda

Int J Hematol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis